FDA approves new Cabometyx indication
The approval of a new indication for Exelixis’ Cabometyx is offering a treatment for patients with liver cancer.
The Food and Drug Administration gave its blessing for Cabometyx (cabozantinib) tablets to treat patients with hepatocellular carcinoma, or HCC, who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the United States.
Cabometyx tablets already have been approved in the United States for the treatment of patients with advanced renal cell carcinoma.
“This new indication for Cabometyx is an important treatment advance for patients with this aggressive form of liver cancer, a community in need of new therapeutic options,” Elexis president and CEO Michael Morrissey said. “This approval is an important milestone as we continue to explore how Cabometyx may benefit people with difficult-to-treat cancers beyond renal cell carcinoma.”
No comments found